AR039358A1 - Formulacion liquida que comprende cetuximab. - Google Patents

Formulacion liquida que comprende cetuximab.

Info

Publication number
AR039358A1
AR039358A1 ARP020102605A ARP020102605A AR039358A1 AR 039358 A1 AR039358 A1 AR 039358A1 AR P020102605 A ARP020102605 A AR P020102605A AR P020102605 A ARP020102605 A AR P020102605A AR 039358 A1 AR039358 A1 AR 039358A1
Authority
AR
Argentina
Prior art keywords
cetuximab
cancer cells
egf receptor
liquid formulation
receptor
Prior art date
Application number
ARP020102605A
Other languages
English (en)
Inventor
Robert Muller
Christiane Bachmann
Martini-Marr Ulrike Dr
Mahler Hanns Chistian Dr
Udo Haas
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR039358A1 publication Critical patent/AR039358A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulación farmacéutica líquida que comprende Cetuximab, un buffer fosfato con un pH entre 6 y 8, y un éster de ácido graso de polioxietilen sorbitán. El Cetuximb es un anticuerpo monoclonal quimérico contra el receptor del factor de crecimiento epidérmico (receptor EGF). El bloqueo del receptor EGF por anticuerpos tales como el Cetuximab actúa contra los tumores en varios planos, p. ej. inhibiendo la proliferación de células cancerígenas, reduciendo la angiogénesis mediada por tumores, induciendo la apoptosis de las células cancerígenas e incrementando los efectos tóxicos de la radioterapia y la quimioterapia convencional. Esta formulación líquida que contiene Cetuximab es adecuada para la administración parenteral, se tolera bien y es estable durante un almacenamiento de al menos un ano a temperatura ambiente. Además, tiene una composición simple y no comprende sustancias auxiliares cuestionables desde el punto de vista toxicológico.
ARP020102605A 2001-07-13 2002-07-12 Formulacion liquida que comprende cetuximab. AR039358A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10133394A DE10133394A1 (de) 2001-07-13 2001-07-13 Flüssige Formulierung enthaltend Cetuximab

Publications (1)

Publication Number Publication Date
AR039358A1 true AR039358A1 (es) 2005-02-16

Family

ID=7691220

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102605A AR039358A1 (es) 2001-07-13 2002-07-12 Formulacion liquida que comprende cetuximab.

Country Status (18)

Country Link
US (1) US20040170632A1 (es)
EP (1) EP1406658A1 (es)
JP (1) JP2004536129A (es)
KR (1) KR20040018458A (es)
CN (1) CN1231264C (es)
AR (1) AR039358A1 (es)
BR (1) BR0211060A (es)
CA (1) CA2453342A1 (es)
CZ (1) CZ2004189A3 (es)
DE (1) DE10133394A1 (es)
HU (1) HUP0401046A3 (es)
MX (1) MXPA04000340A (es)
PE (1) PE20030433A1 (es)
PL (1) PL364599A1 (es)
RU (1) RU2004102395A (es)
SK (1) SK862004A3 (es)
WO (1) WO2003007988A1 (es)
ZA (1) ZA200401161B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3417875T1 (sl) * 2003-02-10 2021-01-29 Biogen Ma Inc. Formulacija imunoglobulina in metode za njegovo pripravo
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) * 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
AU2005211890B2 (en) * 2004-02-12 2011-07-28 Merck Patent Gmbh Highly concentrated liquid formulations of anti-EGFR antibodies
KR20070008710A (ko) * 2004-04-27 2007-01-17 웰스테트 바이올로직스 코포레이션 바이러스 및 캄토테신을 이용한 암치료 방법
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
PT1859793E (pt) * 2005-02-28 2011-07-05 Eisai R&D Man Co Ltd Uso combinado inovador de um composto de sulfonamida no tratamento oncológico
EP1982718A4 (en) 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd ANTICANCER PHARMACEUTICAL COMPOSITION
EP2015775B1 (en) 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
TW200831129A (en) * 2006-10-06 2008-08-01 Amgen Inc Stable formulations
AU2007309616B2 (en) * 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
CN107773755B (zh) * 2016-08-31 2021-06-22 上海津曼特生物科技有限公司 抗表皮生长因子受体单克隆抗体的注射液制剂
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN112566652A (zh) 2018-06-25 2021-03-26 Jcr制药股份有限公司 含有蛋白的水性液体制剂
US20210290644A1 (en) * 2018-08-31 2021-09-23 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
AU6267896A (en) * 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
IL122910A (en) * 1995-07-27 2002-05-23 Genentech Inc Stable isotonic protein formulation that has undergone lyophilization

Also Published As

Publication number Publication date
HUP0401046A2 (en) 2006-04-28
ZA200401161B (en) 2004-10-22
RU2004102395A (ru) 2005-05-27
CZ2004189A3 (cs) 2004-05-12
BR0211060A (pt) 2004-07-20
EP1406658A1 (de) 2004-04-14
HUP0401046A3 (en) 2006-11-28
MXPA04000340A (es) 2004-05-04
CN1231264C (zh) 2005-12-14
PL364599A1 (en) 2004-12-13
DE10133394A1 (de) 2003-01-30
PE20030433A1 (es) 2003-05-24
CN1527724A (zh) 2004-09-08
KR20040018458A (ko) 2004-03-03
SK862004A3 (en) 2004-07-07
WO2003007988A1 (de) 2003-01-30
US20040170632A1 (en) 2004-09-02
CA2453342A1 (en) 2003-01-30
JP2004536129A (ja) 2004-12-02

Similar Documents

Publication Publication Date Title
AR039358A1 (es) Formulacion liquida que comprende cetuximab.
CL2009002199A1 (es) Anticuerpo que se une especificamente a epitope de cripto; composicion farmaceutica que comprende dicho anticuerpo; uso del anticuerpo para disminuir el crecimiento de un tumor in vitro; metodo para modular el crecimiento de celulas de tumor in vitro en una muestra; anticuerpo humanizado (div. sol. n° 831-2002).
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CO5640082A2 (es) Compuestos derivados de succinimida heterociclicos fusionados que son moduladores de la funcion del receptor de la hormona nuclear y composiciones farmaceuticas que los contienen
CO6270340A2 (es) Formulaciones de anticuerpos anti-cd20 estables a la temperatura y cizalladura
BR0209777A (pt) Formulações lìquidas estáveis
TW200505890A (en) Breast cancer-resistant protein inhibitor
ATE348635T1 (de) Injizierbare depotformulierung enthaltend iloperidonkrystalle
GT200100061A (es) Compuestos y composiciones farmaceuticas y metodos para inhibir kinasas proteinicas.
AR034389A1 (es) Monohidrato cristalino de bromuro de tiotropio, procedimiento para su preparacion, su utilización para la preparacion de un medicamento, un medicamento que lo contiene, los hidratos cristalinos del bromuro de tiotropio y un procedimiento para preparacion de estos hidratos cristalinos
UY27961A1 (es) Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas
BR0107535A (pt) Uso de carotenóides e forma de dosagem unitária destes
NZ719036A (en) Anti-pdl1 antibody formulations
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
AR021849A1 (es) Composiciones y metodos para la inmunoterapia especifica de wt1
CA2454587A1 (en) Stable lyophilized pharmaceutical formulation of igg antibodies
CO2019009034A2 (es) Formulación de anticuerpo monoclonal anti-vrs referencia cruzada a solicitudes relacionadas
DE3884044D1 (de) Orale Darreichungsformen mit verzögerter Abgabe.
BR0013081A (pt) Pirimidino-2,4,6-trionas inibidoras de metaloproteinases
UY29181A1 (es) Derivados de bencenosulfonamidas n-sustituidos, composiciones que los contienen, procesos de preparación y aplicaciones
GB2380675A (en) Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives
ATE483455T1 (de) Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
AR092325A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
DK1255845T3 (da) Modificerede cytokiner til anvendelse i cancerterapi

Legal Events

Date Code Title Description
FB Suspension of granting procedure